Sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors improve cardiovascular outcomes in heart failure (HF), but their effect on sleep quality (SQ) and patient‐centered outcomes remains unclear. This evidence concerns the gene SLC5A2 and heart failure.